Magnus Persson leaves the Board of Directors of Abliva AB to focus on role as founding partner at Eir Ventures

Abliva AB (Nasdaq Stockholm: ABLI) today announces that Magnus Persson is leaving the company’s Board of Directors at his own request, to focus on his role as founding Partner at Eir Ventures, a recently started fund for investments in the life science sector.

Magnus Persson has been a board member of Abliva since 2019.

“I would like to thank Magnus Persson for a fine effort in the board’s work and wish him the best of luck in working with Eir Ventures”, says David Laskow-Pooley, Chairman of Abliva AB.

Abliva – Delivering mitochondrial health

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD+ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, is in preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

Magnus Persson leaves the Board of Directors of Abliva AB to focus on role as founding partner at Eir Ventures